/PRNewswire/ Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the.
Novo Holdings realised Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020. The result is based on a strong performance from both the Novo Group companies and the Novo Holdings Investment Portfolio, with the latter generating a highly satisfactory return of 15% for .
/PRNewswire/ Novo Holdings realised Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020. The result is.
Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie· Deal value of US$ 1 billion with US$ 130 million upfront· Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing&m.